Veracyte reported $467.88M in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Agenus USD 78.81M 16.47M Jun/2026
Agilent USD 4.69B 70M Jun/2026
Anika Therapeutics USD 99.19M 5.63M Jun/2026
Arrowhead Research USD 1.29B 382.19M Sep/2026
Bruker USD 2.16B 67.9M Sep/2026
Heron Therapeutics USD 209.11M 20.73M Sep/2026
Illumina USD 3.04B 201M Sep/2026
Intrexon USD 23.72M 45.04M Jun/2024
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
Laboratory Of America USD 3.97B 151.3M Sep/2026
Ligand Pharmaceuticals USD 608.23M 848.88M Sep/2026
Myriad Genetics USD 289M 23.8M Jun/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Roche Holding CHF 35.44B 3.29B Jun/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Siemens EUR 68.86B 3.72B Sep/2026
Sonic Healthcare AUD 2.3B 52.76M Dec/2024
Thermo Fisher Scientific USD 25.62B 2.25B Sep/2026
Veracyte USD 467.88M 106.9M Sep/2026
Waters USD 3.9B 186M Jun/2026